Jazz Pharmaceuticals plc Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Jazz Pharmaceuticals plc (JAZZ) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $26.71 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-24
- Jazz Pharmaceuticals plc unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $26.71M, a 0.70% increase from fiscal 2024.
- Jazz Pharmaceuticals plc unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $26.52M, a 11.39% increase from fiscal 2023.
- Jazz Pharmaceuticals plc unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $23.81M, a 11.12% increase from fiscal 2022.
- Jazz Pharmaceuticals plc unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $21.43M, a 19.35% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2025-12-31 | $26.71M 10-K · filed 2026-02-24 |
| 2024-12-31 | $26.52M 10-K · filed 2026-02-24 |
| 2023-12-31 | $23.81M 10-K · filed 2026-02-24 |
| 2022-12-31 | $21.43M 10-K · filed 2025-02-26 |
| 2021-12-31 | $26.57M 10-K · filed 2024-02-28 |
| 2020-12-31 | $25.17M 10-K · filed 2023-03-01 |
| 2019-12-31 | $22.12M 10-K · filed 2022-03-01 |
| 2018-12-31 | $18.18M 10-K · filed 2021-02-23 |
| 2017-12-31 | $13.17M 10-K · filed 2020-02-25 |
| 2016-12-31 | $3.28M 10-K · filed 2019-02-26 |
| 2015-12-31 | $268.00K 10-K · filed 2018-02-27 |
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-23 |
| 2012-12-31 | $0.00 10-K · filed 2013-02-26 |
| 2011-12-31 | $0.00 10-K · filed 2013-02-26 |
| 2010-12-31 | $23.00K 10-K · filed 2013-02-26 |
| 2009-12-31 | $6.00K 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |